ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Amazon Pharmacy will deliver Eli Lilly's Zepbound, other drugs to customers' doorsteps

Amazon Pharmacy is now a third-party dispensing provider for LillyDirect, the pharmaceutical company's telehealth platform, and gives patients access to more weight-loss drugs.

Amazon will now deliver pharmaceutical giant Eli Lilly's diabetes and weight-loss medications to customers' doors. 

Amazon Pharmacy announced Wednesday that it will serve as a third-party dispensing provider for LillyDirect, the pharmaceutical company's new telehealth site. 

The platform launched earlier this year so patients in the U.S. suffering from obesity, diabetes or migraines can work with independent health care providers and get direct home delivery of select Lilly medicines through third-party pharmacy dispensing services to manage their disease.

AMAZON LAUNCHES NEW SUBSCRIPTION PRESCRIPTION DRUG SERVICE

With Amazon's logistics and supply chain management, customers will be able to get the medications to their door with ongoing tracking updates and access to customer care teams.

Both Lilly and Novo Nordisk have been reaping the financial benefits of the feverish demand for their respective GLP-1 drugs. 

AMAZON’S NEW TELEHEALTH SERVICE TO OFFER CARE FOR COMMON CONDITIONS

Lilly's Mounjaro and Zepbound, and Novo's Ozempic and Wegogy have been highly coveted products ever since celebrities and others on social media touted their weight-loss effects. But while the use of these drugs is increasing, so are concerns that they aren't being used appropriately. 

Lilly's drug tirzepatide was approved in November for the treatment of obesity under the brand name Zepbound. The approval came more than a year after the drug had been approved for people with Type 2 diabetes and sold under the brand name Mounjaro.

Novo's drug semaglutide was approved in 2017 for people with Type 2 diabetes and sold under the brand name Ozempic. It was approved for chronic weight management under the brand name Wegovy three years ago.

Medical professionals, as well as Lilly and Novo, have repeatedly stated that these drugs aren't lifestyle medications.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Lilly even launched a recent campaign to underscore the importance of obesity treatment as a disease and the appropriate use of anti-obesity medications.

Amazon said Wednesday that its clinical pharmacists "review each incoming prescription for accuracy, appropriateness, and drug interactions." 

It also has staff available to provide guidance on how to administer injections, drug interactions, side effects and cost considerations. 

Its clinical team is available 24/7, Amazon said. 

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.